Controlled Substances Prescription Monitoring Program

Doug Skvarla
Program Director

Arizona State Board of Pharmacy
<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>When did the PMP begin in Arizona?</td>
<td>2008</td>
</tr>
<tr>
<td>How many times was the AZPMP queried in 2018?</td>
<td>8.9 m</td>
</tr>
<tr>
<td>How many other state PMPs are connected to the Arizona PMP?</td>
<td>35 + MHS</td>
</tr>
</tbody>
</table>
### What is the PMP?

**Patient Report**

**Report Prepared:** 05/14/2019

**Data Range:** 06/14/2014 - 05/14/2019

#### Linked Records

<table>
<thead>
<tr>
<th>Name</th>
<th>DOB</th>
<th>ID</th>
<th>Gender</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Patient</td>
<td>01/01/1990</td>
<td>1</td>
<td>female</td>
<td>496 Falls Dr, Wolseley 10B.81</td>
</tr>
<tr>
<td>Test Patient</td>
<td>01/01/1990</td>
<td>2</td>
<td>unknown</td>
<td>11440 LAM STATION RD. STE 201 LOUISVILLE KY 40215</td>
</tr>
</tbody>
</table>

#### Report Criteria

**Find Name:** [Last, First Name: patient, DOB: (1/1/1990)]

#### Summary

<table>
<thead>
<tr>
<th>Summary</th>
<th>Opioids* (excluding buprenorphine)</th>
<th>Buprenorphine*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Prescriptions</td>
<td>15</td>
<td>0.0</td>
</tr>
<tr>
<td>Total Private Pay</td>
<td>14</td>
<td>0.0</td>
</tr>
<tr>
<td>Total MME/day</td>
<td>7</td>
<td>0.0</td>
</tr>
<tr>
<td>Total 30 Day Avg MME/Day</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Total Prescriptions</td>
<td>5</td>
<td>0.0</td>
</tr>
</tbody>
</table>

#### Prescriptions

<table>
<thead>
<tr>
<th>Filled</th>
<th>ID</th>
<th>Written</th>
<th>Drug</th>
<th>QTY</th>
<th>Days</th>
<th>Prescriber</th>
<th>Rx #</th>
<th>Pharmacy*</th>
<th>Refills</th>
<th>Daily Dose</th>
<th>Pyret Type</th>
<th>PMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/03/19</td>
<td>1</td>
<td>05/03/19</td>
<td>OXYCONTIN 20 MG TABLET</td>
<td>50.0</td>
<td>0</td>
<td>Go</td>
<td>7777888</td>
<td>Dew [2020]</td>
<td>0</td>
<td>0</td>
<td>AZ</td>
<td>1</td>
</tr>
</tbody>
</table>
# Patient Utilization Report

Report Prepared: 05/14/2019

Date Range: 05/14/2014 – 05/14/2019

## Patient Report

**test patient**

<table>
<thead>
<tr>
<th>Name</th>
<th>DOB</th>
<th>ID</th>
<th>Gender</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Patient</td>
<td>01/01/1900</td>
<td>1</td>
<td>female</td>
<td>555 Fake Dr, Wichita KS 6</td>
</tr>
<tr>
<td>TEST PATIENT</td>
<td>01/01/1900</td>
<td>3</td>
<td></td>
<td>555 FAKE DR WITCHITA KS 67203</td>
</tr>
<tr>
<td>Test Patient</td>
<td>01/01/1900</td>
<td>2</td>
<td>unknown</td>
<td>10401 LINN STATION RD STE 201 LOUISVILLE KY 40223</td>
</tr>
</tbody>
</table>

## Report Criteria

**First Name: test, Last Name: patient, DOB: 01/01/1900**

### Summary

<table>
<thead>
<tr>
<th>Summary</th>
<th>Opioids* (excluding buprenorphine)</th>
<th>Buprenorphine*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Prescriptions</td>
<td>15 Current Qty</td>
<td>0.0 Current Qty</td>
</tr>
<tr>
<td>Total Private Pay</td>
<td>14 Current MME/day</td>
<td>0.0 Current mg/day</td>
</tr>
<tr>
<td>Total Prescribers</td>
<td>7 30 Day Avg MME/day</td>
<td>0.0 30 Day Avg mg/day</td>
</tr>
<tr>
<td>Total Pharmacies</td>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>
### Prescriptions

<table>
<thead>
<tr>
<th>Filled</th>
<th>ID</th>
<th>Written</th>
<th>Drug</th>
<th>QTY</th>
<th>Days</th>
<th>Prescriber</th>
<th>Rx #</th>
<th>Pharmacy</th>
<th>Refills</th>
<th>Daily Dose</th>
<th>Pymt Type</th>
<th>PMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/02/2018</td>
<td>1</td>
<td>03/02/2018</td>
<td>OXYCONTIN 20 MG TABLET</td>
<td>60.0</td>
<td>0</td>
<td>Ca Tes</td>
<td>7789456</td>
<td>Dave' (0000)</td>
<td>0</td>
<td>7.5 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>10/05/2017</td>
<td>2</td>
<td>10/05/2017</td>
<td>OXYCODONE-ACETAMINOPHEN 5-325</td>
<td>1.0</td>
<td>1</td>
<td>Ap Pre</td>
<td>10052017</td>
<td>Appri (0000)</td>
<td>0</td>
<td>7.5 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>10/05/2017</td>
<td>2</td>
<td>10/05/2017</td>
<td>HYDROCODON-ACETAMINOPHEN 10-325</td>
<td>1.0</td>
<td>1</td>
<td>Ap Pre</td>
<td>20171005</td>
<td>Appri (0000)</td>
<td>0</td>
<td>7.5 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>01/10/2017</td>
<td>3</td>
<td>01/10/2017</td>
<td>OXYCONTIN 80 MG TABLET</td>
<td>90.0</td>
<td>30</td>
<td>CA TES</td>
<td>TP000005</td>
<td>Carol (2222)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>01/04/2017</td>
<td>3</td>
<td>01/04/2017</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>30</td>
<td>AL TES</td>
<td>TP0000000</td>
<td>Alice (4567)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>01/03/2017</td>
<td>3</td>
<td>01/03/2017</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>30</td>
<td>DA TES</td>
<td>TP0000008</td>
<td>Dave' (0000)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>12/14/2016</td>
<td>3</td>
<td>12/14/2016</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>60</td>
<td>EV TES</td>
<td>TP0000011</td>
<td>Dave' (0000)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>12/14/2016</td>
<td>3</td>
<td>12/14/2016</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>30</td>
<td>DA TES</td>
<td>TP0000009</td>
<td>Dave' (0000)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>12/11/2016</td>
<td>3</td>
<td>12/11/2016</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>25</td>
<td>BO TES</td>
<td>TP0000002</td>
<td>Bob's (1111)</td>
<td>0</td>
<td>96.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
</tbody>
</table>
Patient Utilization Report

### Prescribers

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescriber, Appnss</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testprescriber, Carol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TESTPRESCRIBER, EVE</td>
<td>10110 TEST ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67204</td>
<td></td>
</tr>
<tr>
<td>TESTPRESCRIBER, ALICE</td>
<td>1111 FAKE ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67203</td>
<td></td>
</tr>
</tbody>
</table>

### Dispensers

<table>
<thead>
<tr>
<th>Pharmacy</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dave’s PHARMACY CHAIN (0000)</td>
<td>7th TEST ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67212</td>
<td>3165551111</td>
</tr>
<tr>
<td>Dave’s Pharmacy Chain (0000)</td>
<td>7TH TEST ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67212</td>
<td></td>
</tr>
<tr>
<td>Carol’s PHARMACY CHAIN (2222)</td>
<td>2nd NOWHERE ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67206</td>
<td>3365550000</td>
</tr>
<tr>
<td>Bob’s PHARMACY (1111)</td>
<td>1234 NOT-A-REAL-PLACE DR</td>
<td>WICHITA</td>
<td>KS</td>
<td>67202</td>
<td>3160000000</td>
</tr>
<tr>
<td>Appnss Pharmacy (0000)</td>
<td>10401 LNN STATION RD</td>
<td>LOUISVILLE</td>
<td>KY</td>
<td>40223</td>
<td>9652777477</td>
</tr>
</tbody>
</table>
PMP – Total Registrations

- Prescribers
- Prescriber Delegates
- Pharmacists
- Pharmacist Delegates
- Law Enforcement

Total Registrations:
- 0
- 5,000
- 10,000
- 15,000
- 20,000
- 25,000
- 30,000

Mar-18
Mar-19
PMP – Total % of Users

For opioids and benzodiazepines only, 44.6% checked prior to prescribing in March 2019.
Arizona Opioid Epidemic Act
A prescriber who has:
- Valid license from a state licensing board
- Valid DEA registration number(s)

A pharmacist who has:
- Valid license from State Board of Pharmacy
- Employed at facility with valid DEA #
It’s the Law - Who has access the PMP

- Prescribers
- Pharmacists
- Delegates
- Licensing boards
- Medical Examiners

- Law enforcement or criminal justice agencies
- Medicaid fraud investigators
- Individual patients
Prescribers – Patient Report

• Before prescribing an opioid or benzodiazepine

• Must include preceding 12 months of patient history – default setting

• Initial course of treatment/every 3 months during ongoing treatment
Exemptions to Reviewing the Report

- Cancer diagnosis
- Traumatic injury
  - (fractures, amputations, burns)
- Hospice, palliative, end of life care
- Skilled nursing facility
- Medication-Assisted Treatment (MAT)
Pharmacists – Patient Report

- Before dispensing a C2 Controlled Substance
- Past 12 month report (Default)
- For each new course of treatment
Advantages to using the PMP

- Assists in prescribing appropriately
  - *Best Practice/Standard of Care*

- Identify, deter, and prevent abuse and diversion of prescription CS drugs

- Safeguard your DEA number: Protect your identity
Prescription limits – C2 Opioids

- **Initial Prescription**
  - Not more than a 5 day supply

- **Surgical procedure**
  - Not more than a 14 day supply
Daily MME Limit – C2 Opioids

• Not more than 90 MMEs per day

If prescription > 90 MMEs per day

• Must consult with a board-certified pain specialist

• Must prescribe an opioid antagonist
  • Naloxone
Prescribing Limits - Exemptions

- Cancer diagnosis
- Traumatic injury
  - (fractures, amputations, burns)
- Hospice, palliative, end of life care
- Skilled nursing facility
- Medication-Assisted Treatment for substance use disorder
It’s the Law - Prescribers who Dispense

May no longer dispense C2 opioids
  • MAT dispensations are exempt

Must report daily
  • All controlled substances
  • Including “zero” reports
  • MAT dispensations are not report
Integration – PMP Direct to your EHR

I heard it was difficult to use?!?!

PMP Button to EHR
- Saves time
- Keeps focus on patient

Aware system still available

https://pharmacypmp.az.gov
Save Time – Streamlined Workflow

- Exit EHR and go to PMP Site
- Enter username and password
- Navigate to patient request
- Enter patient data
- Determine date range of search
- Select which states to query
- Click Search
Electronic Prescribing of Controlled Substances

EPCS
EPCS Law Updates – HB 2075

- State-wide implementation deadline extended
  - Jan. 1, 2020

- No more waivers!

- Clarifies process if EPCS system is non-operational or unavailable

- Veterinarians are exempt from EPCS mandate until EPCS compliant software is more widely available
Benefits of EPCS

- Decreased forgeries
- Protects DEA #
- Accuracy
- Time Savings
Ultimate Goal: Well-being of patients
Still a Lot of Work to Do

3 Waves of the Rise in Opioid Overdose Deaths

- Commonly Prescribed Opioids: Natural & Semi-Synthetic Opioids and Methadone
- Other Synthetic Opioids: e.g., Tramadol and Fentanyl, prescribed or illicitly manufactured

Wave 1: Rise in Prescription Opioid Overdose Deaths
Wave 2: Rise in Heroin Overdose Deaths
Wave 3: Rise in Synthetic Opioid Overdose Deaths

Additional Resources

OAR Line

Naloxone Access

Prescribing Guidelines
Resources – PMP Website

- Latest announcements/updates
- Training material/FAQs
- Important links and forms
- Contact Information

https://pharmacypmp.az.gov/
Resources – Training Videos

- Registration
- Delegate registration
- Request a patient report
- Understand a patient report
- MyRx - Rxs using their DEA#

https://pharmacypmp.az.gov/pmp-training
Controlled Substances Prescription Monitoring Program

Questions?
Controlled Substances Prescription Monitoring Program

Thanks for Attending!